Monopar Therapeutics Ownership 2024 | Who Owns Monopar Therapeutics Now?

OverviewFinancials Chart

Institutional Ownership

2.60%

Insider Ownership

53.33%

Retail Ownership

44.07%

Institutional Holders

11.00

Monopar Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
MILLENNIUM MANAGEMENT LLC	1.22%	0.00%	194,298	1,917	1.00%	145,335	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.38%	-	60,036	18,837	45.72%	44,906	Jun 30, 2024
TWO SIGMA SECURITIES, LLC	0.29%	0.00%	47,058	47,058	100.00%	34,357	Jun 30, 2024
VANGUARD GROUP INC	0.28%	-	45,167	-	-	32,976	Jun 30, 2024
GERBER, LLC	0.18%	0.02%	28,005	-	-	20,446	Jun 30, 2024
VIRTU FINANCIAL LLC	0.12%	0.00%	18,840	-4,987	-20.93%	14,000	Jun 30, 2024
RAPPAPORT REICHES CAPITAL MANAGEMENT, LLC	0.07%	0.00%	10,695	-	-	7,808	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,922	66	0.84%	5,783	Jun 30, 2024
NEWEDGE ADVISORS, LLC	0.02%	-	3,000	-	-	2,190	Jun 30, 2024
WELLS FARGO & COMPANY/MN	0.02%	-	2,500	963	62.65%	1,825	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	561	61	12.20%	410	Jun 30, 2024
FEDERATION DES CAISSES DESJARDINS DU QUEBEC	0.00%	-	80	-	-	58	Jun 30, 2024
FMR LLC	-	-	-	-5,500	-100.00%	-	Jun 30, 2024
MORGAN STANLEY	-	-	-	-800	-100.00%	-	Jun 30, 2024
HRT FINANCIAL LP	-	-	-	-32,113	-100.00%	-	Jun 30, 2024
UBS GROUP AG	-	-	-	-2,568	-100.00%	-	Jun 30, 2024

Monopar Therapeutics's largest institutional shareholder is MILLENNIUM MANAGEMENT LLC, holding 1.22% of the company's total share outstanding, currently valued at $145.34K. The top 10 institutional shareholders own together 2.61% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GERBER, LLC	0.18%	0.02%	28,005	-	-	20,446	Jun 30, 2024
RAPPAPORT REICHES CAPITAL MANAGEMENT, LLC	0.07%	0.00%	10,695	-	-	7,808	Jun 30, 2024
VIRTU FINANCIAL LLC	0.12%	0.00%	18,840	-4,987	-20.93%	14,000	Jun 30, 2024
TWO SIGMA SECURITIES, LLC	0.29%	0.00%	47,058	47,058	100.00%	34,357	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,922	66	0.84%	5,783	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	1.22%	0.00%	194,298	1,917	1.00%	145,335	Jun 30, 2024
NEWEDGE ADVISORS, LLC	0.02%	-	3,000	-	-	2,190	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.38%	-	60,036	18,837	45.72%	44,906	Jun 30, 2024
VANGUARD GROUP INC	0.28%	-	45,167	-	-	32,976	Jun 30, 2024
WELLS FARGO & COMPANY/MN	0.02%	-	2,500	963	62.65%	1,825	Jun 30, 2024
FEDERATION DES CAISSES DESJARDINS DU QUEBEC	0.00%	-	80	-	-	58	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	561	61	12.20%	410	Jun 30, 2024
FMR LLC	-	-	-	-5,500	-100.00%	-	Jun 30, 2024
MORGAN STANLEY	-	-	-	-800	-100.00%	-	Jun 30, 2024
HRT FINANCIAL LP	-	-	-	-32,113	-100.00%	-	Jun 30, 2024
UBS GROUP AG	-	-	-	-2,568	-100.00%	-	Jun 30, 2024

The largest Monopar Therapeutics shareholder by % of total assets is GERBER, LLC. The company owns 28.00K shares of Monopar Therapeutics (MNPR), representing 0.02% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TWO SIGMA SECURITIES, LLC	0.29%	0.00%	47,058	47,058	100.00%	34,357	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.38%	-	60,036	18,837	45.72%	44,906	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	1.22%	0.00%	194,298	1,917	1.00%	145,335	Jun 30, 2024
WELLS FARGO & COMPANY/MN	0.02%	-	2,500	963	62.65%	1,825	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,922	66	0.84%	5,783	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	561	61	12.20%	410	Jun 30, 2024
FEDERATION DES CAISSES DESJARDINS DU QUEBEC	0.00%	-	80	-	-	58	Jun 30, 2024
VANGUARD GROUP INC	0.28%	-	45,167	-	-	32,976	Jun 30, 2024
NEWEDGE ADVISORS, LLC	0.02%	-	3,000	-	-	2,190	Jun 30, 2024
RAPPAPORT REICHES CAPITAL MANAGEMENT, LLC	0.07%	0.00%	10,695	-	-	7,808	Jun 30, 2024
GERBER, LLC	0.18%	0.02%	28,005	-	-	20,446	Jun 30, 2024
MORGAN STANLEY	-	-	-	-800	-100.00%	-	Jun 30, 2024
UBS GROUP AG	-	-	-	-2,568	-100.00%	-	Jun 30, 2024
VIRTU FINANCIAL LLC	0.12%	0.00%	18,840	-4,987	-20.93%	14,000	Jun 30, 2024
FMR LLC	-	-	-	-5,500	-100.00%	-	Jun 30, 2024
HRT FINANCIAL LP	-	-	-	-32,113	-100.00%	-	Jun 30, 2024

As of Jun 30 2024, Monopar Therapeutics's largest institutional buyer is TWO SIGMA SECURITIES, LLC. The company purchased 47.06K stocks of MNPR, valued at $34.36K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HRT FINANCIAL LP	-	-	-	-32,113	-100.00%	-	Jun 30, 2024
FMR LLC	-	-	-	-5,500	-100.00%	-	Jun 30, 2024
VIRTU FINANCIAL LLC	0.12%	0.00%	18,840	-4,987	-20.93%	14,000	Jun 30, 2024
UBS GROUP AG	-	-	-	-2,568	-100.00%	-	Jun 30, 2024
MORGAN STANLEY	-	-	-	-800	-100.00%	-	Jun 30, 2024
GERBER, LLC	0.18%	0.02%	28,005	-	-	20,446	Jun 30, 2024
RAPPAPORT REICHES CAPITAL MANAGEMENT, LLC	0.07%	0.00%	10,695	-	-	7,808	Jun 30, 2024
NEWEDGE ADVISORS, LLC	0.02%	-	3,000	-	-	2,190	Jun 30, 2024
VANGUARD GROUP INC	0.28%	-	45,167	-	-	32,976	Jun 30, 2024
FEDERATION DES CAISSES DESJARDINS DU QUEBEC	0.00%	-	80	-	-	58	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	561	61	12.20%	410	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	7,922	66	0.84%	5,783	Jun 30, 2024
WELLS FARGO & COMPANY/MN	0.02%	-	2,500	963	62.65%	1,825	Jun 30, 2024
MILLENNIUM MANAGEMENT LLC	1.22%	0.00%	194,298	1,917	1.00%	145,335	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.38%	-	60,036	18,837	45.72%	44,906	Jun 30, 2024
TWO SIGMA SECURITIES, LLC	0.29%	0.00%	47,058	47,058	100.00%	34,357	Jun 30, 2024

As of Jun 30 2024, Monopar Therapeutics's biggest institutional seller is HRT FINANCIAL LP. The company sold -32.11K shares of MNPR, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TWO SIGMA SECURITIES, LLC	0.29%	0.00%	47,058	47,058	100.00%	34,357	Jun 30, 2024

Monopar Therapeutics's largest new institutional shareholder by number of shares is TWO SIGMA SECURITIES, LLC, purchased 47.06K shares, valued at $34.36K, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HRT FINANCIAL LP	-	-	-	-32,113	-100.00%	-	Jun 30, 2024
FMR LLC	-	-	-	-5,500	-100.00%	-	Jun 30, 2024
UBS GROUP AG	-	-	-	-2,568	-100.00%	-	Jun 30, 2024
MORGAN STANLEY	-	-	-	-800	-100.00%	-	Jun 30, 2024

Monopar Therapeutics's largest sold out institutional shareholder by shares sold is HRT FINANCIAL LP, sold -32.11K shares, valued at -, as of undefined.

Monopar Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY CONCORD STREET TRUST	0.00%	41,088	-111	-0.27%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	45,167	-45,167	-50.00%	Mar 31, 2024
NORTHERN FUNDS	0.00%	13,043	-	-	Mar 28, 2024
USAA MUTUAL FUNDS TRUST	0.00%	766	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	784	-	-	Mar 31, 2024
iSHARES TRUST	0.00%	10,606	-	-	Mar 31, 2024

Monopar Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 41.09K shares, compromising 0.00% of its total assets.

Monopar Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 24	11	-26.67%
31 Mar, 24	15	7.14%
31 Dec, 23	14	-
30 Sep, 23	14	75.00%
30 Jun, 23	8	-27.27%
31 Mar, 23	11	10.00%
31 Dec, 22	10	25.00%
30 Sep, 22	8	-20.00%
30 Jun, 22	10	-9.09%
31 Mar, 22	11	-
31 Dec, 21	11	37.50%
30 Sep, 21	8	-
30 Jun, 21	8	-33.33%
31 Mar, 21	12	100.00%
31 Dec, 20	6	50.00%
30 Sep, 20	4	-
30 Jun, 20	4	-
31 Mar, 20	4	-20.00%
31 Dec, 19	5	-

As of 30 Jun 24, 11 institutions are holding Monopar Therapeutics's shares, representing a decrease of -26.67% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 24	415,162	5.04%
31 Mar, 24	395,228	45.63%
31 Dec, 23	271,392	-9.95%
30 Sep, 23	301,390	56.62%
30 Jun, 23	192,440	-16.91%
31 Mar, 23	231,615	16.55%
31 Dec, 22	198,728	-0.16%
30 Sep, 22	199,038	-4.23%
30 Jun, 22	207,829	1.65%
31 Mar, 22	204,459	0.13%
31 Dec, 21	204,200	2.95%
30 Sep, 21	198,340	5.85%
30 Jun, 21	187,375	-3.82%
31 Mar, 21	194,809	178.66%
31 Dec, 20	69,910	-7.22%
30 Sep, 20	75,352	32.77%
30 Jun, 20	56,755	217.90%
31 Mar, 20	17,853	-32.97%
31 Dec, 19	26,635	-

Monopar Therapeutics (MNPR) has 415.16K shares outstanding as of 30 Jun 24, up 5.04% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 24	2.60%	31.78%
31 Mar, 24	2.86%	77.37%
31 Dec, 23	1.92%	38.11%
30 Sep, 23	2.25%	104.16%
30 Jun, 23	1.47%	47.02%
31 Mar, 23	1.77%	72.38%
31 Dec, 22	1.56%	64.17%
30 Sep, 22	1.56%	57.65%
30 Jun, 22	1.65%	62.52%
31 Mar, 22	1.62%	60.50%
31 Dec, 21	1.64%	65.90%
30 Sep, 21	1.58%	70.93%
30 Jun, 21	1.49%	57.88%
31 Mar, 21	1.60%	405.74%
31 Dec, 20	0.63%	136.88%
30 Sep, 20	0.68%	238.61%
30 Jun, 20	0.53%	1881.76%
31 Mar, 20	0.17%	206.16%
31 Dec, 19	0.29%	-

As of 30 Jun 24, Monopar Therapeutics is held by 2.60% institutional shareholders, representing a 31.78% growth compared to 31 Mar 24.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 24	6	-14.29%
31 Mar, 24	7	-12.50%
31 Dec, 23	8	14.29%
30 Sep, 23	7	75.00%
30 Jun, 23	4	-20.00%
31 Mar, 23	5	-16.67%
31 Dec, 22	6	100.00%
30 Sep, 22	3	200.00%
30 Jun, 22	1	-75.00%
31 Mar, 22	4	-20.00%
31 Dec, 21	5	66.67%
30 Sep, 21	3	-40.00%
30 Jun, 21	5	-37.50%
31 Mar, 21	8	166.67%
31 Dec, 20	3	50.00%
30 Sep, 20	2	-33.33%
30 Jun, 20	3	-
31 Mar, 20	3	-40.00%
31 Dec, 19	5	-

6 institutional shareholders have increased their position in MNPR stock as of 30 Jun 24 compared to 7 in the previous quarter (a -14.29% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 24	1	-50.00%
31 Mar, 24	2	-
31 Dec, 23	2	-60.00%
30 Sep, 23	5	400.00%
30 Jun, 23	1	-
31 Mar, 23	1	-66.67%
31 Dec, 22	3	200.00%
30 Sep, 22	1	-75.00%
30 Jun, 22	4	100.00%
31 Mar, 22	2	100.00%
31 Dec, 21	1	-50.00%
30 Sep, 21	2	100.00%
30 Jun, 21	1	-50.00%
31 Mar, 21	2	-
31 Dec, 20	2	100.00%
30 Sep, 20	1	-
30 Jun, 20	-	-100.00%
31 Mar, 20	1	-
31 Dec, 19	-	-

1 institutional shareholders have reduced their position in MNPR stock as of 30 Jun 24 compared to 2 in the previous quarter (a -50.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 24	11	-26.67%	415,162	5.04%	2.60%	31.78%	6	-14.29%	1	-50.00%
31 Mar, 24	15	7.14%	395,228	45.63%	2.86%	77.37%	7	-12.50%	2	-
31 Dec, 23	14	-	271,392	-9.95%	1.92%	38.11%	8	14.29%	2	-60.00%
30 Sep, 23	14	75.00%	301,390	56.62%	2.25%	104.16%	7	75.00%	5	400.00%
30 Jun, 23	8	-27.27%	192,440	-16.91%	1.47%	47.02%	4	-20.00%	1	-
31 Mar, 23	11	10.00%	231,615	16.55%	1.77%	72.38%	5	-16.67%	1	-66.67%
31 Dec, 22	10	25.00%	198,728	-0.16%	1.56%	64.17%	6	100.00%	3	200.00%
30 Sep, 22	8	-20.00%	199,038	-4.23%	1.56%	57.65%	3	200.00%	1	-75.00%
30 Jun, 22	10	-9.09%	207,829	1.65%	1.65%	62.52%	1	-75.00%	4	100.00%
31 Mar, 22	11	-	204,459	0.13%	1.62%	60.50%	4	-20.00%	2	100.00%
31 Dec, 21	11	37.50%	204,200	2.95%	1.64%	65.90%	5	66.67%	1	-50.00%
30 Sep, 21	8	-	198,340	5.85%	1.58%	70.93%	3	-40.00%	2	100.00%
30 Jun, 21	8	-33.33%	187,375	-3.82%	1.49%	57.88%	5	-37.50%	1	-50.00%
31 Mar, 21	12	100.00%	194,809	178.66%	1.60%	405.74%	8	166.67%	2	-
31 Dec, 20	6	50.00%	69,910	-7.22%	0.63%	136.88%	3	50.00%	2	100.00%
30 Sep, 20	4	-	75,352	32.77%	0.68%	238.61%	2	-33.33%	1	-
30 Jun, 20	4	-	56,755	217.90%	0.53%	1881.76%	3	-	-	-100.00%
31 Mar, 20	4	-20.00%	17,853	-32.97%	0.17%	206.16%	3	-40.00%	1	-
31 Dec, 19	5	-	26,635	-	0.29%	-	5	-	-	-

Monopar Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 21, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	20,508	$0.74	$15.25K	186,132
Jun 21, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.86	$10.32K	165,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.90	$10.80K	153,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.93	$11.18K	141,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.91	$10.92K	129,624
Jun 05, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.78	$9.36K	117,624
Jun 05, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.76	$9.12K	105,624
May 31, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.64	$7.73K	93,624
May 31, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.64	$7.68K	81,624

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 21, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	20,508	$0.74	$15.25K	186,132
Jun 21, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.86	$10.32K	165,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.90	$10.80K	153,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.93	$11.18K	141,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.91	$10.92K	129,624
Jun 05, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.78	$9.36K	117,624
Jun 05, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.76	$9.12K	105,624
May 31, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.64	$7.73K	93,624
May 31, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.64	$7.68K	81,624

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 02, 2024	Cittadine Andrew	officer	Chief Operating Officer	F-InKind	Sell	2,019	$0.73	$1.48K	193,065
Jul 02, 2024	Cittadine Andrew	officer	Chief Operating Officer	M-Exempt	Sell	8,952	-	-	73,271
Jul 02, 2024	Tsuchimoto Kim R	director, officer	Chief Financial Officer	M-Exempt	Sell	9,957	-	-	74,412
Jul 02, 2024	Tsuchimoto Kim R	director, officer	Chief Financial Officer	F-InKind	Sell	2,998	$0.73	$2.19K	57,429
Jul 02, 2024	Robinson Chandler	director, officer	Chief Executive Officer	F-InKind	Sell	8,684	$0.73	$6.35K	265,922
Jul 02, 2024	Robinson Chandler	director, officer	Chief Executive Officer	M-Exempt	Sell	24,476	-	-	173,335

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 03, 2024	Radhakrishnan Karthik	officer	Chief Financial Officer	A-Award	Buy	125,000	$0.74	$92.67K	125,000
Jul 03, 2024	Radhakrishnan Karthik	officer	-		Buy	-	-	-	-
Jul 02, 2024	Cittadine Andrew	officer	Chief Operating Officer	M-Exempt	Buy	8,952	-	-	195,084
Jul 02, 2024	Cittadine Andrew	officer	Chief Operating Officer	F-InKind	Sell	2,019	$0.73	$1.48K	193,065
Jul 02, 2024	Cittadine Andrew	officer	Chief Operating Officer	M-Exempt	Sell	8,952	-	-	73,271
Jul 02, 2024	Tsuchimoto Kim R	director, officer	Chief Financial Officer	M-Exempt	Sell	9,957	-	-	74,412
Jul 02, 2024	Tsuchimoto Kim R	director, officer	Chief Financial Officer	M-Exempt	Buy	9,957	-	-	60,427
Jul 02, 2024	Tsuchimoto Kim R	director, officer	Chief Financial Officer	F-InKind	Sell	2,998	$0.73	$2.19K	57,429
Jul 02, 2024	Robinson Chandler	director, officer	Chief Executive Officer	M-Exempt	Buy	24,476	-	-	274,606
Jul 02, 2024	Robinson Chandler	director, officer	Chief Executive Officer	F-InKind	Sell	8,684	$0.73	$6.35K	265,922
Jul 02, 2024	Robinson Chandler	director, officer	Chief Executive Officer	M-Exempt	Sell	24,476	-	-	173,335
Jun 21, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	20,508	$0.74	$15.25K	186,132
Jun 21, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.86	$10.32K	165,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.90	$10.80K	153,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.93	$11.18K	141,624
Jun 17, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.91	$10.92K	129,624
Jun 05, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.78	$9.36K	117,624
Jun 05, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.76	$9.12K	105,624
May 31, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.64	$7.73K	93,624
May 31, 2024	Cittadine Andrew	officer	Chief Operating Officer	P-Purchase	Buy	12,000	$0.64	$7.68K	81,624

The last insider sell of Monopar Therapeutics's stock was made by Cittadine Andrew on Jul 02 2024, selling 2,019 shares at $0.73 per share (valued at $1.48K). The last insider buy of MNPR was made by Cittadine Andrew on Jun 21 2024, buying 20,508 shares at $0.74 per share (worth $15.25K).

Monopar Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	1	-	-
Q2 2024	15	7	214.29%
Q1 2024	6	10	60.00%
Q4 2023	7	10	70.00%
Q3 2023	7	10	70.00%
Q2 2023	7	10	70.00%
Q1 2023	24	14	171.43%
Q4 2022	9	10	90.00%
Q3 2022	7	10	70.00%
Q2 2022	6	8	75.00%
Q1 2022	27	14	192.86%
Q4 2021	7	10	70.00%
Q3 2021	8	10	80.00%
Q2 2021	9	11	81.82%
Q1 2021	22	15	146.67%
Q4 2020	4	4	100.00%
Q3 2020	4	4	100.00%
Q2 2020	4	4	100.00%
Q1 2020	19	4	475.00%
Q4 2019	7	2	350.00%

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Monopar Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	-	-
Q2 2024	10	-	-
Q1 2024	-	-	-
Q4 2023	-	-	-
Q3 2023	-	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q4 2022	2	-	-
Q3 2022	-	-	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q4 2021	-	-	-
Q3 2021	-	-	-
Q2 2021	-	-	-
Q1 2021	-	5	-
Q4 2020	-	-	-
Q3 2020	-	-	-
Q2 2020	-	-	-
Q1 2020	-	-	-
Q4 2019	5	-	-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Monopar Therapeutics's stocks.

Monopar Therapeutics Peer Ownership

Ticker	Company
ENOB	Renovaro Biosciences Inc.
PMVP	PMV Pharmaceuticals, Inc.
MLYS	Mineralys Therapeutics, Inc.
SCPH	scPharmaceuticals Inc.
KTTA	Pasithea Therapeutics Corp.
AVTE	Aerovate Therapeutics, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
ACXP	Acurx Pharmaceuticals, Inc.
SCPS	Scopus BioPharma Inc.
ANTX	AN2 Therapeutics, Inc.
PHVS	Pharvaris N.V.
RZLT	Rezolute, Inc.
CADL	Candel Therapeutics, Inc.
DMAC	DiaMedica Therapeutics Inc.
PEPG	PepGen Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
ADAG	Adagene Inc.
MOLN	Molecular Partners AG

MNPR Ownership FAQ

Who Owns Monopar Therapeutics?

Monopar Therapeutics is owned by institutional shareholders (2.60%), insiders (53.33%), and public (44.07%). The largest institutional shareholder of Monopar Therapeutics is MILLENNIUM MANAGEMENT LLC (1.22% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

Who are the major institutional shareholders of Monopar Therapeutics?

Monopar Therapeutics's major institutional shareholders are MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA SECURITIES, LLC, VANGUARD GROUP INC, and GERBER, LLC. The top five shareholders own together 2.34% of the company's share outstanding.

How many Monopar Therapeutics shareholders are there?

As of Jun 2024, there are 11 institutional shareholders of Monopar Therapeutics.

What percentage of Monopar Therapeutics is owned by MILLENNIUM MANAGEMENT LLC?

MILLENNIUM MANAGEMENT LLC owns 194.3K shares of Monopar Therapeutics, representing 1.22% of the company's total shares outstanding, valued at $145.34K (as of Jun 2024).

What percentage of Monopar Therapeutics is owned by GEODE CAPITAL MANAGEMENT, LLC?

As of Jun 2024, GEODE CAPITAL MANAGEMENT, LLC holds 60.04K shares of Monopar Therapeutics (MNPR), compromising 0.38% of the company, valued at $44.91K.

What percentage of Monopar Therapeutics is owned by TWO SIGMA SECURITIES, LLC?

TWO SIGMA SECURITIES, LLC is the third largest holder of Monopar Therapeutics. The company owns 47.06K of the company's shares outstanding (worth $34.36K).